Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Chris Markoch

Viking Therapeutics: High Risk, High Reward Play

Viking Therapeutics Inc. (NASDAQ: VKTX) stock is soaring after the company delivered its third-quarter earnings report. The clinical-stage biopharmaceutical company is not profitable and is not generating revenue. However, investors cheered the company’s news that Phase 3 trials for its injectable weight loss treatment, VK2735, are proceeding as scheduled.

It’s impossible to ignore the importance of the company’s dual GLP-1/GIP receptor agonist. The company has other drugs in its pipeline. For example, its VK2809 candidate is in Phase 2 trials to treat non-alcoholic steatohepatitis (NASH). It also has an oral drug, VK0214, which targets a rare genetic neurological disorder.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.